Exposure-toxicity relationship of cabozantinib in patients with renal cell cancer and salivary gland cancer.

ABSTRACT: Cabozantinib is registered in fixed 60 mg dose. However, 46% to 62% of patients in the registration studies needed a dose reduction due to toxicity. Improved clinical efficacy has been observed in renal cell carcinoma patients (RCC) with a cabozantinib exposure greater than 750 μg/L. In our study we explored the cabozantinib exposure in patients with different tumour types. We included RCC patients from routine care and salivary gland carcinoma (SGC) patients from a phase II study with ≥1 measured C_min at steady-state. The geometric mean (GM) C_min at the starting dose, at 40 mg and at best tolerated dose (BTD) were compared between both tumour types. Forty-seven patients were included. All SGC patients (n = 22) started with 60 mg, while 52% of RCC patients started wit

SUBMITTER: Krens SD 

PROVIDER: S-EPMC9291492 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature